Search

Displaying results 2151 - 2160 of 10000 in total
  1. Drug

    Artenimol

    go.drugbank.com/drugs/DB11638
    ApprovedInvestigational

    It was first authorized for market by the European Medicines Agency in October 2011 in combination with [DB13941] as the product Eurartesim. … Artenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated *Plasmodium falciparum* infections [FDA Label].

    Mixtures: EURARTESIM 320 MG/40 MG FILM COATED TABLETS
  2. Drug

    Bisoctrizole

    go.drugbank.com/drugs/DB11262
    Approved

    10% [F90]. … Bisoctrizole, or methylene bis-benzotriazolyl tetramethylbutylphenol, is a broad-spectrum organic UV filter that is marketed as Tinosorb M [A19212].

    Mixtures: SPF 50, Emulsion SPF 50+
  3. Indication

    Disseminated mycobacterium avium complex infection

    go.drugbank.com/conditions/DBCOND0025049
    Drugs: Streptomycin
    Synonyms: Disseminated Mycobacterium avium complex, Disseminated mycobacterium avium complex infection
  4. Drug

    Calaspargase pegol

    go.drugbank.com/drugs/DB14730
    ApprovedInvestigational

    Calaspargase pegol, by _Shire_ pharmaceuticals, was approved by the FDA on December 20, 2018 for acute lymphoblastic anemia (ALL) [L4890]. … Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Omega-3-carboxylic acids

    go.drugbank.com/drugs/DB09568
    ApprovedWithdrawn

    It is a complex mixture of the free fatty acids form containing eicosapentaenoic acid and docosahexaenoic acid as the most abundant species found in a proportion of 55% and 20% respectively. … The omega-3 carboxylic acid (OM3-CA) is a new formulation of omega-3 fatty acids that present an enhanced bioavailability in the treatment of dyslipidemia.

  6. Drug

    Lonafarnib

    go.drugbank.com/drugs/DB06448
    ApprovedInvestigational

    Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature … [L23414, L23544] Lonafarnib was granted FDA approval on November 20, 2020, and is the first FDA-approved treatment for HGPS and other related progeroid laminopathies.[L23414, L23549]

  7. Drug

    Nebicapone

    go.drugbank.com/drugs/DB14849
    Investigational

    of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg). … Nebicapone is under investigation in clinical trial NCT03097211 (Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose

  8. Drug

    Butriptyline

    go.drugbank.com/drugs/DB09016
    ApprovedWithdrawn

    Butriptyline is a tricyclic antidepressant which has been used in Europe since 1974. It is the isobutyl side chain homologue of amitriptyline.

  9. Drug

    mRNA-1345

    go.drugbank.com/drugs/DB18739
    ApprovedInvestigational

    mRESVIA was first approved in the EU and US in 2024 for use in patients 60 years of age and older. … [L53403,L53393] It is additionally under investigation for maternal use and use in children.[A274028,L53438,L53443]

    Categories: Complex Mixtures
  10. Drug

    Elexacaftor

    go.drugbank.com/drugs/DB15444
    ApprovedInvestigational

    for the _F508del-CFTR_ gene - this represents approximately 70[A187373]-90%[A187361,A187355] of all CF patients. … [A187361] It received FDA approval in October 2019 in combination with [tezacaftor] and [ivacaftor] as the combination product Trikafta<sup>TM</sup>.